Literature DB >> 24993745

The role of miR-29 family members in malignant hematopoiesis.

Sona Kollinerova1, Stefano Vassanelli, Martin Modriansky.   

Abstract

AIMS: MicroRNAs of the miR-29 family members were one of the first microRNAs identified as possible therapeutic agents in malignant hematopoiesis. The aim of our review is to summarize the current state of knowledge on miR-29 family members.
METHODS: We performed literature searches involving miR-29 family members and their relationship to individual hematological malignancies, namely acute myeloid leukemia (AML), chronic lymphoblastic leukemia (CLL) and chronic myeloid leukemia (CML). We also searched for subgroups of hematological malignancies, e.g. multiple myeloma, that are regarded as members of the acute or chronic types of leukemias.
RESULTS: A number of genes appear to be regulated by miR-29 family members in various physiological and pathological situations. In our view regulation of Tcl-1, Mcl-1 and DNA methyltransferases is relevant in case of hematological malignancies, hence these are the focus of this review. miR-29 family members also function during normal T-cell and B-cell development.
CONCLUSION: MiR-29 family members appear to govern some general features in commonly heterogenous hematological malignancies and therefore form a potential target for treatment.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24993745     DOI: 10.5507/bp.2014.029

Source DB:  PubMed          Journal:  Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub        ISSN: 1213-8118            Impact factor:   1.245


  11 in total

1.  A therapeutic approach towards microRNA29 family in vascular diabetic complications: A boon or curse?

Authors:  Aishwarya P Dasare; Piyush Gondaliya; Akshay Srivastava; Kiran Kalia
Journal:  J Diabetes Metab Disord       Date:  2019-05-11

2.  MiR-15a-5p negatively regulates cell survival and metastasis by targeting CXCL10 in chronic myeloid leukemia.

Authors:  Dan Chen; Dijiong Wu; Keding Shao; Baodong Ye; Jian Huang; Yanting Gao
Journal:  Am J Transl Res       Date:  2017-09-15       Impact factor: 4.060

Review 3.  Exploring epigenetic and microRNA approaches for γ-globin gene regulation.

Authors:  Athena Starlard-Davenport; Ashley Fitzgerald; Betty S Pace
Journal:  Exp Biol Med (Maywood)       Date:  2021-07-22

Review 4.  MicroRNAs mediated regulation of MAPK signaling pathways in chronic myeloid leukemia.

Authors:  Chiranjib Chakraborty; Ashish Ranjan Sharma; Bidhan Chandra Patra; Manojit Bhattacharya; Garima Sharma; Sang-Soo Lee
Journal:  Oncotarget       Date:  2016-07-05

5.  Clinical response to azacitidine therapy depends on microRNA-29c (miR-29c) expression in older acute myeloid leukemia (AML) patients.

Authors:  Aleksandra Butrym; Justyna Rybka; Dagmara Baczyńska; Rafał Poręba; Kazimierz Kuliczkowski; Grzegorz Mazur
Journal:  Oncotarget       Date:  2016-05-24

6.  Bortezomib-inducible long non-coding RNA myocardial infarction associated transcript is an oncogene in multiple myeloma that suppresses miR-29b.

Authors:  Yunfeng Fu; Xiao Liu; Fangrong Zhang; Siyi Jiang; Jing Liu; Yanwei Luo
Journal:  Cell Death Dis       Date:  2019-04-09       Impact factor: 8.469

Review 7.  The Non-Canonical Aspects of MicroRNAs: Many Roads to Gene Regulation.

Authors:  Christiaan J Stavast; Stefan J Erkeland
Journal:  Cells       Date:  2019-11-19       Impact factor: 6.600

Review 8.  Role of Chronic Lymphocytic Leukemia (CLL)-Derived Exosomes in Tumor Progression and Survival.

Authors:  Nancy Nisticò; Domenico Maisano; Enrico Iaccino; Eleonora Vecchio; Giuseppe Fiume; Salvatore Rotundo; Ileana Quinto; Selena Mimmi
Journal:  Pharmaceuticals (Basel)       Date:  2020-09-14

9.  miR-29a sensitizes the response of glioma cells to temozolomide by modulating the P53/MDM2 feedback loop.

Authors:  Qiudan Chen; Weifeng Wang; Shuying Chen; Xiaotong Chen; Yong Lin
Journal:  Cell Mol Biol Lett       Date:  2021-05-27       Impact factor: 5.787

10.  miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors.

Authors:  Sonali Sharma; Gabriela Mladonicka Pavlasova; Vaclav Seda; Katerina Amruz Cerna; Eva Vojackova; Daniel Filip; Laura Ondrisova; Veronika Sandova; Lenka Kostalova; Pedro F Zeni; Marek Borsky; Jan Oppelt; Kvetoslava Liskova; Leos Kren; Andrea Janikova; Sarka Pospisilova; Stacey M Fernandes; Medhat Shehata; Laura Z Rassenti; Ulrich Jaeger; Michael Doubek; Matthew S Davids; Jennifer R Brown; Jiri Mayer; Thomas J Kipps; Marek Mraz
Journal:  Blood       Date:  2021-05-06       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.